Project Grant R44GM149106

Award Date 5/1/23
Completion Date 7/31/26
Dollars Obligated $3.8M
Federal Grant Program
93.859
Assistance Type
Project Grant
Place of Performance
Houston, TX 77204, USA
Similar Awards
This federal Project Grant award from the National Center for Advancing Translational Sciences (NCATS), under CFDA 93.350, provides $349,171 to Cellchorus Inc. to develop an integrated computer vision system called LF-TIMING (Label-Free TIMING). The goal is to enable large-scale, label-free profiling of cell-cell interactions, particularly between immune cells and tumor cells. The LF-TIMING system will leverage deep neural networks to accurately analyze phase-contrast video recordings,...
This National Science Foundation (NSF) Project Grant award under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program provides $305,000 to Cellecho, Inc. to develop a microchip-based technology that leverages sound waves and electric fields to manipulate cells and sequentially deliver customizable combinations of genetic materials. The goal is to make advanced cell engineering more accessible and streamlined, accelerating discoveries in cell and gene therapy, biotechnology,...
This $353,204 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) supports the development of a novel technology called Cell-MAPP by Pumpkinseed Technologies Inc., a for-profit company located in Palo Alto, California. The goal of this Phase I Small Business Innovation Research (SBIR) project is to demonstrate and advance Cell-MAPP, a live-cell monitoring system that enables continuous, high-throughput analysis of T cell states...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) project grant, awarded to Selight, LLC, aims to develop a rapid diagnostic instrument for assessing the health and viability of chimeric antigen receptor (CAR) T cells prior to their use in cancer immunotherapy. The $304,733 award, effective July 1, 2025 through June 30, 2026, will fund the design, engineering, and prototyping of an optical metabolic...
This $295,924 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) aims to develop and demonstrate a high-yield microfluidic device for the enrichment and capture of CD3+ T cells. This device is intended to improve the manufacturing of autologous and allogenic engineered cell therapies such as CAR-T, which currently have time-consuming and costly production processes. The key objectives are to (1)...
This Project Grant award from the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $343,203 to Cyion Technologies LLC to develop a novel in vitro electrophysiology system for high-throughput measurement of intracellular action potential (IAP) in human-derived cardiomyocytes. The system leverages a 3D nanoelectrode array (NEA) technology to enable scalable recordings of IAP signals from many individual cardiomyocytes. This...
This Project Grant award of $665,616 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) supports the development of a novel micro-capsule technology to enable high-throughput analysis of millions of live cell-cell interactions in parallel. The technology aims to address a major unmet need in screening functional antibodies and peptides, evaluating ligand-receptor specificity, and determining cell adhesion affinities....
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under CFDA 93.859 Biomedical Research and Research Training program provides $306,860 to Mixedlcmedia LLC, a small disadvantaged business, to develop and evaluate a prototype ultra-low flow liquid chromatography platform based on their proprietary porous layer open-tubular (PLOT) and monolithic nanocolumn technologies. The goal is to create a commercialization-ready LC system that enables deep proteomic...
This Project Grant awarded by the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training federal grant program (CFDA 93.859), aims to advance the commercialization of an innovative automated cell culturing system. The $295,038 award to Altvivo, Inc. will enable the development of capabilities to: 1) induce different cell lineages from stem cells via localized drug delivery to achieve complex tissue patterns; and 2) perform non-disruptive...
Partillion Bioscience Corp. was awarded a $659,037 Project Grant from the National Institutes of Health's National Institute of General Medical Sciences to develop reagent products enabling high-throughput screening and selection of single cells based on secreted bio-products. Under the Biomedical Research and Research Training program (CFDA 93.859), Partillion plans to transition its lab-on-a-particle technology—highlighted as a 2020 SLAS Innovation Award winner—into the first reagent product...

DYNAMIC SINGLE-CELL ANALYSIS INSTRUMENT TO EVALUATE IMMUNE CELL FUNCTION - 7. PROJECT SUMMARY/ABSTRACT RECENT DECADES HAVE BEEN MARKED BY A REVOLUTION IN SINGLE-CELL ANALYTICAL TECHNIQUES, INSTRUMENTS AND SOFTWARE TOOLS THAT HAVE MARKEDLY IMPROVED OUR UNDERSTANDING OF BIOLOGY. A HIGH-PROFILE EXAMPLE HAS BEEN THE EMERGENCE OF SINGLE-CELL SEQUENCING TO MOVE FROM BULK GENOMIC AND TRANSCRIPTOMIC ANALYSIS TO SINGLE-CELL RESOLUTION THAT REVEALS THE HETEROGENEITY OF INDIVIDUAL CELLS. SIMILAR TRENDS HAVE BEEN OBSERVED IN PROTEIN ANALYSIS, SPATIAL TRANSCRIPTOMICS, AND OTHER DISCIPLINES. HOWEVER, THERE REMAINS A CRITICAL UNMET NEED IN UNDERSTANDING INDIVIDUAL CELLULAR FUNCTION, MOVEMENT, INTERACTIONS, AND OTHER MEASURES OF PERFORMANCE. THE GENESIS OF CELLS AS LIVING DRUGS REQUIRES THE DEVELOPMENT OF TECHNOLOGIES THAT CAN CHARACTERIZE THE FUNCTION AND PERFORMANCE OF MASSIVE NUMBERS OF CELLS AT SINGLE-CELL RESOLUTION TO SUPPORT DEVELOPMENT OF NEW THERAPIES AND CLINICAL BIOMARKERS. UNFORTUNATELY, EXISTING TECHNOLOGIES ARE EITHER NOT SCALABLE, ARE CELL-DESTRUCTIVE AND SO CANNOT EVALUATE CELLS AND THEIR INTERACTIONS OVER TIME, OR DO NOT PROVIDE SINGLE-CELL RESOLUTION. CELLCHORUS EVALUATES THE PERFORMANCE AND INTERACTIONS OF THOUSANDS OF INDIVIDUAL CELLS BY APPLYING TIME- LAPSE IMAGING MICROSCOPY IN NANOWELL GRIDS (TIMING) WITH NEURAL NETWORK-BASED ARTIFICIAL INTELLIGENCE (AI) TO IDENTIFY, TRACK, AND CHARACTERIZE BEHAVIORS AND INTERACTIONS OF DISEASE CELLS TOGETHER WITH T-CELLS AND OTHER EFFECTOR CELLS. THE PLATFORM HAS BEEN VALIDATED TECHNICALLY AND COMMERCIALLY IN AN ACADEMIC SETTING AND AN EARLY ACCESS LABORATORY, BUT THIS MODEL DOES NOT SCALE. WE WILL DEVELOP AND RIGOROUSLY VALIDATE A CHRONOS INSTRUMENT THAT DELIVERS DYNAMIC SINGLE-CELL ANALYSIS BASED ON THE TIMING PLATFORM AND APPLYING OUR EXISTING AI SOFTWARE AND ALGORITHMS. THE CHRONOS INSTRUMENT WILL ALLOW SCIENTISTS, RESEARCHERS, AND MANUFACTURING EXPERTS TO APPLY DYNAMIC SINGLE-CELL ANALYSIS TO CATALYZE DEVELOPMENT AND MANUFACTURE OF NOVEL THERAPIES IN INFECTIOUS DISEASES, ONCOLOGY, AND OTHER MEDICAL SCIENCES.

Posted 4/28/23, 12:00 AM